Skip to content

Isaac Cohen

2 papers in the library · 31 citations · publishing 2021

Papers

Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database

Scientific Reports March 16, 2021 Isaac Cohen, Tigran Makunts, Ruben Abagyan et al. 30 citations

Using FDA drug safety surveillance data, nearly one thousand reports of MDMA use were analyzed to evaluate risks of death when MDMA is taken alone or with other medications. Several drug classes—including MDMA metabolites or analogs, anesthetics, muscle relaxants, amphetamines and stimulants, benzodiazepines, ethanol, and opioids—along with the antidepressants bupropion, sertraline, venlafaxine, and citalopram, and the antipsychotic olanzapine, showed increased odds ratios for reported risk of death. The authors call for future clinical trials to assess whether these drug–drug interactions pose actual harm in controlled medical settings.

Three regulatory compliant test systems show no signs of MDMA-related genotoxicity

Journal of Psychopharmacology August 31, 2021 Isaac Cohen, Laken Barber, Tyson Paul Dubnicka et al. 1 citation

3,4-Methylenedioxymethamphetamine (MDMA)-assisted therapy is highly effective for posttraumatic stress disorder (PTSD). Previous research on MDMA's potential to damage DNA (genotoxicity) has been inconclusive. Three regulatory-compliant studies—a bacterial reverse mutation (Ames) assay, a chromosome aberration test in Chinese hamster ovary cells, and an in vivo micronucleus study in male Sprague Dawley rats—found that MDMA did not cause genotoxic effects at or above clinically relevant concentrations.